- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05659784
Virtually Assisted Home Rehabilitation After Acute STroke (VAST-rehab) (VAST-rehab)
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent provided by the subject or legally authorized representative.
- Occurrence of a hemorrhagic or ischemic stroke
- pre-stroke mRS less than 3
- Qualifying Stroke Event must be confirmed by CT or MRI
- Recommended to participate in self-guided or in-person rehabilitation activities by a physician or rehabilitation therapist
- Must have sufficient cognitive and language abilities to comprehend verbal commands and to carry out the study assessments
- Able to access the internet via a personal device
Exclusion Criteria:
- . History of neurological or other disease resulting in significant functional impairment (e.g.Parkinson's disease, motor neuron disease, moderate dementia, arthritis,contractures or fixed anatomical abnormality).
- Subjects with a severe comorbid disorder that has reasonable likelihood of limiting survival to less than 6 months.
- Any other conditions that, in the opinion of the investigators, would preclude safe and/or effective participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Telerehabilitation
|
Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility as assessed by number of participants that completed all scheduled visits.
Time Frame: end of study(12 weeks form baseline)
|
end of study(12 weeks form baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Functional independence as assessed by the Functional Independence Measure (FIM)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
This is an 18 item questionnaire and each is scored from 1(complete dependence on helper) to 7(complete independence), a higher number indicating more independence
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Patient-Specific Functional Scale
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
This tool allows for Subjects to self report activities of daily living that have been affected by stroke and rate severity of impact on these activities.
This is scored from 0(unable to perform activity) to 10(able to perform activity at the same level as before injury or problem)
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in impact of stroke as assessed by the Stroke Impact Scale (SIS)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
This is a A 59 item questionnaire whereby subjects identify the impact of stroke on strength, hand function, mobility, activities of daily living, memory, communication, emotion, and handicap.
Item responses are scored on a 5-point Likert-style scale.
A score of 1 = an inability to complete the item and a score of 5 = no difficulty experienced at all.
A standardized score ranging from 0 to 100 is calculated for all domains, with higher scores indicating a higher quality of life
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in quality of life as assessed by the EuroQol-5-5level scale (EQ-5D-5L)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
A self reporting, quality of life measurement that asks Subjects to rate their severity of problems related to mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. There are 5 questions in the first section and each question is scored from 0-5,a higher number indicating a worse outcome .There is a visual scale at the end that is scored from 0(worst health) to 100(best health), higher number indicating better outcome . . |
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in cognitive impairment as assessed by the Short Montreal Cognitive Assessment(s-MoCA)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
8 item questionnaire ,with a possible score of 1-5, a lower number indicating higher cognitive impairment
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in performance in activities of daily living as assessed by the Barthel Index
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
This is a scoring technique that measures performance in ten activities of daily living including feeding, wheelchair to bed transfers, grooming ,chair to toilet transfers, walking, using stairs, dressing, and continence of bowels and bladder.
This is a 10 item questionnaire and is scored from 0-100, a higher score indicating higher level of independence.
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in symptoms related to stroke as assessed by the National Institute of Health Stroke Scale(NIHSS)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
the score for each ability is a number between 0(normal functioning) to 4(completely impaired).
The score is calculated by adding the number for each element of the scale with a highest score of 42, a higher score meaning more impairment.
|
Baseline, end of study (about 13-14 weeks after baseline)
|
|
Change in degree of disability or dependence as measured by the Modified Rankin Score(mRS)
Time Frame: Baseline, end of study (about 13-14 weeks after baseline)
|
mRS is a 6 point disability scale with possible scores from 0(no disability) to 5(disability requiring constant care) a higher score indicating more disability
|
Baseline, end of study (about 13-14 weeks after baseline)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sean Savitz, MD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-20-0384
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University Hospital HeidelbergCompletedAcute Ischemic Stroke | Acute Ischemic Stroke AIS | Acute Ischemic Stroke PatientsGermany
Clinical Trials on Telerehabilitation
-
University of SalernoAzienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'AragonaRecruiting
-
Saglik Bilimleri UniversitesiCompletedQuality of Life | Fatigue | Muscle Weakness | Pulmonary Disease | COPD | Respiratory Disease | Dyspnea | Muscle Strength | Functional Capacity | Severe Chronic Obstructive Pulmonary Disease | Motor Imagery | Muscle; AccessoryTurkey
-
Biruni UniversityNot yet recruitingPremature Birth of Newborn | Motor Delay | Risky BabyTurkey (Türkiye)
-
Marmara UniversityCompletedHemiparetic Cerebral PalsyTurkey
-
Bright Cloud International CorpNational Cancer Institute (NCI); Rutgers, The State University of New JerseyRecruitingCognitive Impairment, MildUnited States
-
University of Eastern FinlandOulu University Hospital; Kuopio University HospitalRecruiting
-
Sakarya Applied Sciences UniversityNot yet recruitingMusculoskeletal Diseases | Postural; Defect | DriveTurkey
-
King Saud UniversityRecruitingKnee OsteoarthritisSaudi Arabia
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingCoronavirus Infections | Quality of Life | Covid19 | Respiratory Failure | ARDS | Dyspnea | Respiratory Rehabilitation | Sars-CoV-2 | Interstitial PneumoniaItaly
-
SOS Oxygene MediterraneeRecruitingExercise | Chronic Respiratory DiseaseFrance